Legal notices

1. Our details

This website is owned and operated by Inserm Transfert, This email address is being protected from spambots. You need JavaScript enabled to view it., Project Manager (Tel.: +33 1 55 03 01 04; Address: 7 Rue Watt, 75013 Paris, France)

  • Design & Programming: ML-Com, France
  • Hosting: OVH, 140 quai du Sartel, 59100 Roubaix, France, Phone: +33 899 701 761


2. Disclaimer

Inserm Transfert maintains this website to enhance public access to information about Ebovac2. Our goal is to keep this information timely and accurate. If errors are brought to our attention, we will try to correct them. However, Inserm Transfert accepts no responsibility or liability whatsoever with regard to the information on this site.

This information is:

  • of a general nature only and is not intended to address the specific circumstances of any particular individual or entity
  • not necessarily comprehensive, complete, accurate or up to date
  • sometimes linked to external sites over which Inserm Transfert have no control and for which Inserm Transfert assumes no responsibility

Ebovac2 is a research program. The content of this website is not intended to give medical diagnosis, treatment or medical advice.


3. Privacy policy

The site complies with the regulations on data processing, data files and individual liberties set out in the General Data Protection Regulation (EU Regulation 2016/679) (GDPR) and the French Data files and Individual Liberties defined by Law no. 78-17, as amended in the Privacy policy.


4. Copyright notice

All rights reserved.

This information may be freely used and copied for educational and other non-commercial purposes, provided that any reproduction of data be accompanied by an acknowledgement of Ebovac2 as the source (© Ebolavac2).
This does not apply to the pages and images with explicitly reserved reproduction right: © followed by the right owner and the year of first circulation. Reproduction of the latter requires prior authorization from the Ebovac2 for the pages.

NEWS

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings

×

Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as ReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions